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Abstract
Background: Previous analysis clustered 1,238 individuals from the general population Genetics of Lipid Lowering
Drugs Network (GOLDN) study by the size of their fasting very low-density, low-density and high-density
lipoproteins (VLDL, LDL, HDL) using latent class analysis. From two of the eight identified groups (N = 251), ~75%
of individuals met Adult Treatment Panel III criteria for the metabolic syndrome (MetS). Both showed small LDL
diameter (mean = 19.9 nm); however, group 1 (N = 200) had medium VLDL diameter (mean = 53.1 nm) while
group 2 had very large VLDL diameter (mean = 65.74 nm). Group 2 additionally showed significantly more insulin
resistance (IR), and accompanying higher waist circumference and fasting glucose and triglycerides (all P < .01).
Since lipoprotein lipase hydrolyzes triglyceride in the VLDL-LDL cascade, we examined whether these two patterns
of lipoprotein diameter were associated with differences across two lipoprotein lipase (LPL) gene variants: D9N
(rs1801177) and S447X (rs328).
Findings: Mixed linear models that controlled for age, sex, center of data collection, and family pedigree revealed
no differences between the two groups for the D9N polymorphism (P = .36). However, group 2 contained
significantly more carriers (25%) of the 447X variant than group 1 (14%; P = .04).
Conclusions: This was the first study this kind to show an association between LPL and large VLDL particle size
within the MetS, a pattern associated with higher IR. Future work should extend this to larger samples to confirm
these findings, and examine the long term outcomes of those with this lipoprotein diameter pattern.
Keywords: GOLDN, lipoprotein, lipoprotein lipase, Metabolic syndrome
Findings
The MetS is characterized by three or more of the fol-
lowing features: increased waist circumference (WC),
high triglycerides (TGs), lowered high density cholesterol
(HDL-C), hypertension and impaired fasting glucose [1].
Shifts in overall lipoprotein diameter to smaller LDL and
HDL particles, and to larger VLDL particles have addi-
tionally been shown to associate with the individual
features of the MetS [2].
Our previous research grouped individuals according to
the fasting diameters of their VLDL, LDL and HDL parti-
cles. Two groups emerged where individuals, on average,
met the adult treatment panel (ATP) III criteria for the
MetS. Both groups had small LDL diameters (mean =
19.9 nm), but one group with larger VLDL diameters
(65.74 vs 53.1 nm) showed higher IR as measured by
homeostatic model assessment (HOMA-IR; Table 1); and
increased features of the MetS associated with higher IR:
higher fasting glucose, TG, and WC (Table 1).
LPL hydrolyzes TGs from VLDL forming LDL, thus is a
source of lipoprotein size heterogeneity. We therefore
aimed to examine whether there were differences in two
variants in the LPL gene between two groups of MetS indi-
viduals, defined by their fasting lipoprotein diameter
pattern.
Materials and Methods
Participants and study design
The study sample includes 251 men and women partici-
pating in the general population of the GOLDN study.
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The majority of participants were re-recruited from
three-generational pedigrees from two field centers in
Minnesota and Utah. Nearly all individuals were of Eur-
opean descent. The study protocol has been published
elsewhere [3], and was approved by the institutional
review boards of the Universities of Alabama, Minne-
sota, and Utah and Tufts University.
Latent class analysis (LCA) was used to group all
GOLDN individuals according to the diameter of their
fasting (8-hour fast) VLDL, LDL and HDL particles,
determined by nuclear resonance spectroscopy. LCA is a
form of cluster analysis that groups individuals based on
similarities within specified measures, and uses an itera-
tive approach to determine the number of groups
(classes) that best explains the population variance and
covariance in the measures [4]. Initially, all participants
are considered to be in a single class and classes are
added until an additional class does not improve the fit
of the model, as assessed using the log Bayes Factor
(logBF). The LCA was implemented using the TRAJ Pro-
cedure in SAS [5]. As the LCA uses maximum likeli-
hood estimation, the absolute diameter was standardized
within each fraction of HDL, LDL and VLDL to ease
optimization.
LCA grouped all GOLDN individuals into 8 classes
(groups) according their fasting VLDL, LDL and HDL
diameters. For two groups (N = 251), the average number
of MetS features per member (3.5; Table 1) indicated that
the majority of individuals within these groups met ATP-
III criteria for the MetS. The two groups were not distin-
guished by the diameter of their LDL or HDL particles
but by that of their VLDL particles (Table 1). The current
analysis examined these groups for differences in three
variants within the LPL gene.
Genotype data
Genomic data was isolated from blood samples using
routine DNA isolation sets (Qiagen, Valencia, CA,
USA), using a TaqMan assay with allele-specific probes
on the ABI Prism 7900HT Sequence Detection System
(Applied Biosystems, Foster City, CA, USA) according
to the standardized laboratory protocols.
SNP selection
Three nonsynonymous cSNPs at LPL codons 9, 291, and
447, namely, D9N, M107 and S447X were chosen for
literature reports of genetic associations or lipid-related
biological function. The minor allele frequency (MAF)
of M107 was 0, and so excluded from analysis.
Statistical analysis
All analyses were conducted in SAS v9.2. Hardy-Wein-
berg equilibrium (HWE) was determined using c2 analy-
sis. For genotype-phenotype associations, regression
analysis was conducted using the “PROC GENMOD”
command with genotype frequency, age, age2 and age3,
sex, and center of data collection as predictors, and LCA
group as the outcome. Pedigree was treated as a fixed
random effect. To increase power, carriers of the minor
allele for each genotype were compared to non carriers.
Results
Participant characteristics
Lipoprotein, demographic and MetS-related characteris-
tics are shown in Table 1.
LPL genotypes
Genotype frequencies did not deviate from HWE expec-
tations (P < .05). At the D9N locus, individuals were
either homozygous for D9 allele (frequency = .94) or
heterozygous (frequency = .06). The S447X locus
showed individuals who were homozygous for the major
allele (S447; frequency = .84), the minor allele (X447;
frequency = .08) or heterozygous (frequency = .16).
Genotype-phenotype associations
The D9N minor allele (MAF = .10) did not show a
group association (P = .36; Table 1); however in the
Table 1 Lipid, demographic, genetic and MetS-related
characteristics for participants by group
Group 1 Group 2
N 200 51
Gender; % male 72 61
Age, y 50.51 (14.99) 50.94 (14.84)
Lipoprotein diameters
VLDL** 53.07 (3.33) 65.74 (4.92)
LDL 19.79 (0.43) 20.05 (0.56)
HDL 8.39 (0.23) 8.45 (0.24)
Sera lipoprotein particle concentrations (nmol/L)





HDL 29.06 (5.49) 30.22 (5.27)
MetS, and related features
Waist circumference; cm 106.54 (14.80) 109.27 (14.26)
Fasting glucose, (mmol/L)** 5.99 (1.19) 6.37 (1.70)
Diabetes, %** 13 24
Fasting TGs (mmol/L)** 2.37 (1.07) 3.43 (3.76)
HOMA-IR* 4.92 (3.08) 6.56 (4.78)
Total No of MetS counts 3.44 (1.19) 3.45 (1.15)
Individuals meeting ATP-III MetS
criteria; %
72.5 76.5
Genotype data, Minor allele carriers, %
LPL S447X* 14 25
D9N 7 4
*P < .05 **P < .001 All models control for age, sex, centre of data collection
and family pedigree.
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fully adjusted model (controlling for age, sex, data col-
lection center and pedigree) there were significantly
more carriers of the minor allele 447X variant (MAF =
.08) in group 2, than group 1 (P = .04).
Discussion
This study provides evidence that the minor allele of the
LPL S774X variant is associated with larger VLDL dia-
meters within groups defined by a lipoprotein diameter
pattern which includes small LDL and HDL particles. The
majority of individuals within these groups met ATP-III
criteria for the MetS, and the pattern of large VLDL in
addition to the small LDL and HDL particles additionally
associates with higher IR, as well as the highest WC, fast-
ing glucose and TGs, and diabetes prevalence. We did not
find any association with lipoprotein diameter pattern and
the D9N polymorphism.
The LPL S447X variant has been implicated in func-
tional relevance to lipid parameters [6]. The main func-
tions of the LPL S447X variant are the hydrolysis of
plasma TGs, and in mediating the clearance of athero-
genic remnant lipoproteins from the circulation [7].
Total missense, and nonsense mutations lead to type I
hyperlipoproteinemia characterized by the accumulation
of chylomicrons in the circulation [8]. The validity of our
findings is emphazied by previous associations of the
S447X variant with a number of lipid parameters [6,9,10],
and also the presence of the MetS [10], and associations
with peak LDL particle size [11]. However, this is the first
study, to our knowledge, to associate variants with a pat-
tern of particle sizes created using information from all
three fractions of lipoprotein, which associates with the
highest IR within the MetS.
The associations observed in this study must be
viewed with a number of considerations. These include
the small sample size combined with the low MAF for
both variants, and the restriction of results to white
Americans of European descent. It was this modest
sample size that precluded gender stratified analyses.
Nonetheless we provide evidence that the LPL 447X
allele associates with a pattern of particle sizes (small
LDL and HDL, and large VLDL diameters) which, in
turn, is associated with the higher IR, WC, fasting TG
and glucose and diabetes prevalence among groups
where individuals meet ATP-III criteria for the MetS.
Given the small sample size, and novelty of the pheno-
type (lipoprotein diameter pattern) replication in addi-
tional studies is warranted.
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